Coronary/Structural Heart

Siemens Healthineers introduces Somatom Confidence RT Pro CT Scanner

Erlangen, 2016-Sep-27 Somatom Confidence RT Pro is a dedicated CT for radiation therapy DirectDensity algorithm delivers electron density images independent of kV settings, ensuring a smooth simple dose calculation workflow New version of syngo.via RT Image Suite software offers advanced treatment of moving tumors Siemens Healthineers introduced its new Somatom […]

BioCardia Receives U.S. Patent Covering A Method Of Preparing And Characterizing Mesenchymal Cells, Providing Further Protection To Cardiallo Cell Therapy Program

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, today announced the issuance of United States Patent No. 9,301,975 relating to a method of producing mesenchymal stem cells from bone marrow cells in […]

Cardiac Insight, Inc. Continues Steady Beat of Progress with New $4.5 Million Investment and Attracts Prestigious Healthcare M&A Executive, Clifford J. Stocks, to Its Board of Directors

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a U.S. developer of wearable medical devices and diagnostic software, announced today that the company continues to experience a steady beat of market traction and industry endorsement with a recent infusion of $4.5 million into their new C-1 round of funding, currently capped at $10 […]

NaviGate Cardiac Structures, Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient

LAKE FOREST, Calif., Aug. 30, 2017 – NaviGate Cardiac Structures Inc. (“NCSI”) announced today that its GATE™ catheter-guided tricuspid atrioventricular valved stent (A VS) was implanted through the jugular vein six weeks ago into a patient’s transplanted heart that was failing due to severe tricuspid valve insufficiency. The successful implantation […]

Data Published in The Lancet Shows Positive Results at Primary Endpoint in the Treatment of Resistant Hypertension with MobiusHD Device

MOUNTAIN VIEW, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) — Vascular Dynamics, Inc. (VDI), a privately held medical device company developing novel solutions for the treatment of hypertension, today announced European results of the company’s first-in-human trial of its MobiusHD®implant published in The Lancet.  The publication reported an average reduction of 24-hour […]

Neovasc’s Reducer System Reviewed in European Heart Journal

VANCOUVER, Sept. 5, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today announced the European Heart Journal published a clinical review of its Neovasc Reducer™ (“Reducer”) device for the treatment of refractory/persistent angina pectoris, a common and disabling medical condition, and a major public health problem that affects […]

Protembis Announces Successful First-in-Human Use of Its ProtEmbo® Cerebral Protection System in European Trial

AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held medical device company, announced today the first clinical applications of its ProtEmbo® Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo® System is an intra-aortic filter device that deflects embolic material arising during TAVR away from the brain. Darren Mylotte, […]

HeartFlow Announces Positive Medical Coverage Decisions on Non-Invasive HeartFlow® FFRct Analysis from Anthem Blue Cross Blue Shield, Blue Shield of California and Blue Cross and Blue Shield of Alabama

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that Anthem Blue Cross Blue Shield, Blue Shield of California, and Blue Cross and Blue Shield of Alabama have each issued a positive medical policy for the HeartFlow® FFRct Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery […]

Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns

ABBOTT PARK, Ill., Aug. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occurs in approximately 80,000 i,ii pre-term infants in the U.S. each year. […]

ESC Congress 2017: BIOTRONIK’s Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

Landmark Data Published by The Lancet Demonstrates Statistically Significant Lower Event Rates with Orsiro BARCELONA, Spain, August 28, 2017 – BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the […]